Achieve Life Sciences, based in Seattle, is developing cytisinicline, a plant-based alkaloid, for smoking cessation and nicotine addiction, targeting cravings and withdrawal symptoms. The company employs 22 full-time staff.
Achieve Life Sciences (ACHV) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Achieve Life Sciences's actual EPS was -$0.36, missing the estimate of -$0.27 per share, resulting in a -34.98% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
